Smith & Nephew (NYSE:SNN) Stock Rating Upgraded by Zacks Investment Research

Smith & Nephew (NYSE:SNN – Get Rating) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Friday, Zacks.com reports.

According to Zacks, “Smith & Nephew is a global medical device company. The company markets clinically superior products, principally in orthopaedics, endoscopy and wound management to deliver cost-effective solutions, significant physician advantage and real patient benefits. A continuous process of supplying new and innovative products is supported by substantial R&D investment to deliver new levels of healing to patients throughout the world “

SNN has been the topic of a number of other reports. Redburn Partners upgraded Smith & Nephew from a “sell” rating to a “neutral” rating in a research note on Friday, March 4th. UBS Group raised their target price on Smith & Nephew from GBX 1,200 ($14.79) to GBX 1,295 ($15.96) in a research note on Friday, April 29th. JPMorgan Chase & Co. raised their target price on Smith & Nephew from GBX 1,376 ($16.96) to GBX 1,442 ($17.78) in a research note on Wednesday, March 2nd. Royal Bank of Canada assumed coverage on shares of Smith & Nephew in a research note on Tuesday, March 15th. They set an “outperform” rating on the stock. Finally, StockNews.com cut shares of Smith & Nephew from a “strong-buy” rating to a “buy” rating in a research note on Thursday, May 12th. Three research analysts have rated the stock with a hold rating and six have issued a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average price target of $928.33.

SNN stock opened at $31.55 on Friday. The company has a current ratio of 2.08, a quick ratio of 1.21 and a debt-to-equity ratio of 0.51. Smith & Nephew has a 1 year low of $29.40 and a 1 year high of $44.47. The stock’s fifty day moving average is $32.09 and its two-hundred day moving average is $33.29.

A number of institutional investors have recently modified their holdings of the business. Signaturefd LLC raised its position in Smith & Nephew by 10.7% in the fourth quarter. Signaturefd LLC now owns 3,291 shares of the medical equipment provider’s stock worth $114,000 after acquiring an additional 319 shares in the last quarter. Harbor Investment Advisory LLC raised its position in Smith & Nephew by 21.8% in the first quarter. Harbor Investment Advisory LLC now owns 2,442 shares of the medical equipment provider’s stock worth $78,000 after acquiring an additional 437 shares in the last quarter. Highland Capital Management LLC increased its stake in Smith & Nephew by 1.9% in the 4th quarter. Highland Capital Management LLC now owns 24,650 shares of the medical equipment provider’s stock worth $853,000 after purchasing an additional 450 shares in the last quarter. Veriti Management LLC increased its stake in Smith & Nephew by 7.7% in the 4th quarter. Veriti Management LLC now owns 6,336 shares of the medical equipment provider’s stock worth $219,000 after purchasing an additional 455 shares in the last quarter. Finally, Boston Common Asset Management LLC increased its stake in Smith & Nephew by 3.6% in the 4th quarter. Boston Common Asset Management LLC now owns 14,374 shares of the medical equipment provider’s stock worth $498,000 after purchasing an additional 503 shares in the last quarter. Hedge funds and other institutional investors own 26.03% of the company’s stock.

Smith & Nephew Company Profile (Get Rating)

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures.

Featured Stories